BERLEX LABS
BiotechBERLEX LABS is a biotechnology company focused on Oncology.
BERLEX LABS's Key Drugs
BERLEX LABS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BERLEX LABS's Recent FDA Approvals
New NDA/BLA approvals for BERLEX LABS over the last two years — novel drugs only, excluding generics and label supplements.
BERLEX LABS's Therapeutic Areas
BERLEX LABS's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 1 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BERLEX LABS's Top Competitors
BERLEX LABS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BERLEX LABS Pipeline Snapshot
Active clinical trials for BERLEX LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1991-03-05
- Latest
- 2022-05-05
- Applications
- 2